Wendy Kohrt
Concepts (666)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Density | 45 | 2024 | 487 | 6.490 |
Why?
| | Exercise | 68 | 2024 | 2198 | 4.680 |
Why?
| | Body Composition | 54 | 2024 | 693 | 4.280 |
Why?
| | Bone and Bones | 16 | 2021 | 317 | 3.240 |
Why?
| | Parathyroid Hormone | 9 | 2021 | 114 | 3.080 |
Why?
| | Postmenopause | 31 | 2020 | 392 | 3.050 |
Why?
| | Estrogens | 21 | 2024 | 367 | 2.790 |
Why?
| | Menopause | 13 | 2022 | 326 | 2.760 |
Why?
| | Bone Resorption | 7 | 2022 | 81 | 2.500 |
Why?
| | Estradiol | 18 | 2024 | 515 | 2.480 |
Why?
| | Calcium | 7 | 2021 | 1190 | 2.130 |
Why?
| | Premenopause | 11 | 2020 | 125 | 2.090 |
Why?
| | Estrogen Replacement Therapy | 16 | 2019 | 143 | 2.060 |
Why?
| | Gonadotropin-Releasing Hormone | 9 | 2024 | 217 | 2.000 |
Why?
| | Exercise Therapy | 19 | 2025 | 475 | 1.990 |
Why?
| | Endothelium, Vascular | 12 | 2026 | 956 | 1.840 |
Why?
| | Energy Metabolism | 16 | 2024 | 935 | 1.830 |
Why?
| | Estrogens, Conjugated (USP) | 9 | 2017 | 52 | 1.720 |
Why?
| | Walking | 11 | 2021 | 542 | 1.700 |
Why?
| | Glucose | 14 | 2025 | 1048 | 1.700 |
Why?
| | Collagen Type I | 13 | 2021 | 143 | 1.690 |
Why?
| | Parkinson Disease | 16 | 2025 | 599 | 1.650 |
Why?
| | Resistance Training | 9 | 2024 | 186 | 1.630 |
Why?
| | Trigger Points | 3 | 2025 | 15 | 1.550 |
Why?
| | Calcium, Dietary | 7 | 2017 | 52 | 1.540 |
Why?
| | Tension-Type Headache | 2 | 2025 | 11 | 1.460 |
Why?
| | Middle Aged | 130 | 2026 | 36215 | 1.370 |
Why?
| | Lactic Acid | 8 | 2025 | 295 | 1.370 |
Why?
| | Adipose Tissue | 25 | 2022 | 645 | 1.350 |
Why?
| | Aging | 30 | 2026 | 1969 | 1.350 |
Why?
| | Dehydroepiandrosterone | 5 | 2018 | 49 | 1.350 |
Why?
| | Osteoporosis, Postmenopausal | 9 | 2019 | 41 | 1.340 |
Why?
| | Lumbar Vertebrae | 11 | 2021 | 252 | 1.330 |
Why?
| | Femur Neck | 8 | 2020 | 62 | 1.320 |
Why?
| | Aged | 115 | 2026 | 26153 | 1.230 |
Why?
| | Female | 182 | 2025 | 78845 | 1.220 |
Why?
| | Ovary | 4 | 2024 | 233 | 1.200 |
Why?
| | Insulin | 26 | 2022 | 2512 | 1.190 |
Why?
| | Peptides | 12 | 2021 | 998 | 1.150 |
Why?
| | Bicycling | 9 | 2014 | 117 | 1.130 |
Why?
| | Homeostasis | 7 | 2019 | 642 | 1.120 |
Why?
| | Humans | 237 | 2026 | 145475 | 1.120 |
Why?
| | Hormone Replacement Therapy | 9 | 2018 | 107 | 1.110 |
Why?
| | Lipolysis | 6 | 2014 | 44 | 1.090 |
Why?
| | Cardiovascular Diseases | 14 | 2024 | 2187 | 1.080 |
Why?
| | Superficial Back Muscles | 3 | 2025 | 16 | 1.070 |
Why?
| | Muscle, Skeletal | 18 | 2025 | 1789 | 1.060 |
Why?
| | Oxygen Consumption | 32 | 2025 | 718 | 1.030 |
Why?
| | Absorptiometry, Photon | 19 | 2024 | 277 | 0.970 |
Why?
| | Obesity | 21 | 2024 | 3116 | 0.970 |
Why?
| | Testosterone | 9 | 2026 | 416 | 0.950 |
Why?
| | Arthroplasty, Replacement, Knee | 9 | 2017 | 374 | 0.930 |
Why?
| | Sleep Deprivation | 5 | 2022 | 206 | 0.920 |
Why?
| | Adiposity | 5 | 2018 | 532 | 0.910 |
Why?
| | Adipocytes | 6 | 2025 | 223 | 0.910 |
Why?
| | Vascular Stiffness | 6 | 2024 | 486 | 0.900 |
Why?
| | Vasodilation | 9 | 2025 | 521 | 0.900 |
Why?
| | Physical Endurance | 19 | 2015 | 279 | 0.860 |
Why?
| | Motor Activity | 11 | 2015 | 718 | 0.860 |
Why?
| | Insulin Resistance | 12 | 2025 | 1244 | 0.840 |
Why?
| | Sleep | 7 | 2022 | 888 | 0.830 |
Why?
| | Follicle Stimulating Hormone | 6 | 2024 | 266 | 0.830 |
Why?
| | Adult | 91 | 2026 | 40777 | 0.820 |
Why?
| | Male | 134 | 2026 | 72843 | 0.820 |
Why?
| | Quadriceps Muscle | 5 | 2017 | 120 | 0.810 |
Why?
| | Frail Elderly | 6 | 2013 | 136 | 0.810 |
Why?
| | Muscle Strength | 9 | 2024 | 332 | 0.800 |
Why?
| | Weight Loss | 11 | 2024 | 858 | 0.790 |
Why?
| | Dehydroepiandrosterone Sulfate | 4 | 2013 | 43 | 0.760 |
Why?
| | Sweating | 2 | 2019 | 43 | 0.740 |
Why?
| | Glycerol | 8 | 2013 | 90 | 0.720 |
Why?
| | Hypothalamo-Hypophyseal System | 3 | 2018 | 199 | 0.710 |
Why?
| | Pituitary-Adrenal System | 2 | 2018 | 164 | 0.700 |
Why?
| | Regional Blood Flow | 4 | 2025 | 514 | 0.700 |
Why?
| | Leptin | 8 | 2025 | 248 | 0.700 |
Why?
| | Double-Blind Method | 13 | 2018 | 2062 | 0.690 |
Why?
| | Electric Stimulation Therapy | 2 | 2012 | 62 | 0.680 |
Why?
| | Brachial Artery | 8 | 2025 | 208 | 0.680 |
Why?
| | Bone Remodeling | 6 | 2022 | 71 | 0.660 |
Why?
| | Raloxifene Hydrochloride | 3 | 2017 | 15 | 0.650 |
Why?
| | Weight-Bearing | 7 | 2017 | 183 | 0.650 |
Why?
| | Subcutaneous Fat | 3 | 2014 | 79 | 0.640 |
Why?
| | Exercise Test | 18 | 2024 | 630 | 0.610 |
Why?
| | Sex Factors | 10 | 2024 | 2105 | 0.610 |
Why?
| | Skin | 4 | 2019 | 753 | 0.590 |
Why?
| | Osteoarthritis, Knee | 6 | 2018 | 280 | 0.590 |
Why?
| | Corticotropin-Releasing Hormone | 2 | 2018 | 72 | 0.580 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2021 | 345 | 0.570 |
Why?
| | Activities of Daily Living | 7 | 2020 | 444 | 0.560 |
Why?
| | Osteoporosis | 10 | 2024 | 238 | 0.560 |
Why?
| | Headache Disorders | 1 | 2018 | 19 | 0.560 |
Why?
| | Physical Fitness | 9 | 2014 | 207 | 0.550 |
Why?
| | Adaptation, Physiological | 4 | 2012 | 560 | 0.550 |
Why?
| | Massage | 1 | 2018 | 42 | 0.540 |
Why?
| | Heart Rate | 20 | 2025 | 855 | 0.540 |
Why?
| | Randomized Controlled Trials as Topic | 9 | 2024 | 1747 | 0.520 |
Why?
| | Biomarkers | 16 | 2025 | 4295 | 0.520 |
Why?
| | Weight Gain | 3 | 2011 | 561 | 0.510 |
Why?
| | Immunoglobulin G | 3 | 2021 | 892 | 0.510 |
Why?
| | Health | 3 | 2017 | 82 | 0.500 |
Why?
| | Leuprolide | 2 | 2017 | 21 | 0.480 |
Why?
| | Hot Temperature | 1 | 2019 | 396 | 0.480 |
Why?
| | Abdomen | 9 | 2005 | 142 | 0.480 |
Why?
| | Blood Glucose | 22 | 2013 | 2341 | 0.480 |
Why?
| | Ibuprofen | 2 | 2021 | 87 | 0.460 |
Why?
| | Exercise Tolerance | 4 | 2025 | 283 | 0.460 |
Why?
| | Microdialysis | 7 | 2025 | 56 | 0.460 |
Why?
| | Osteogenesis | 5 | 2020 | 204 | 0.460 |
Why?
| | Dietary Supplements | 2 | 2017 | 583 | 0.460 |
Why?
| | Glucose Clamp Technique | 13 | 2014 | 199 | 0.450 |
Why?
| | Glucose Tolerance Test | 12 | 2013 | 360 | 0.450 |
Why?
| | Aged, 80 and over | 24 | 2019 | 8333 | 0.450 |
Why?
| | Medroxyprogesterone Acetate | 5 | 2003 | 33 | 0.450 |
Why?
| | Hypogonadism | 4 | 2024 | 93 | 0.440 |
Why?
| | Antibodies | 1 | 2017 | 397 | 0.440 |
Why?
| | Severity of Illness Index | 11 | 2018 | 2930 | 0.430 |
Why?
| | Selective Estrogen Receptor Modulators | 2 | 2017 | 34 | 0.430 |
Why?
| | Medroxyprogesterone | 2 | 2007 | 11 | 0.430 |
Why?
| | Gonadal Steroid Hormones | 4 | 2021 | 143 | 0.420 |
Why?
| | Young Adult | 21 | 2026 | 14219 | 0.420 |
Why?
| | Autonomic Nervous System Diseases | 2 | 2025 | 37 | 0.410 |
Why?
| | Health Status | 4 | 2020 | 832 | 0.410 |
Why?
| | Perimenopause | 4 | 2022 | 69 | 0.410 |
Why?
| | Thigh | 3 | 2010 | 48 | 0.400 |
Why?
| | Body Weight | 14 | 2024 | 971 | 0.400 |
Why?
| | Running | 9 | 2015 | 233 | 0.380 |
Why?
| | Saliva | 2 | 2005 | 246 | 0.380 |
Why?
| | Femur | 6 | 2018 | 254 | 0.380 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2013 | 162 | 0.380 |
Why?
| | Deuterium | 6 | 2019 | 100 | 0.370 |
Why?
| | Cognition Disorders | 2 | 2015 | 541 | 0.370 |
Why?
| | Carotid Arteries | 6 | 2024 | 208 | 0.360 |
Why?
| | Sweat | 4 | 2019 | 51 | 0.360 |
Why?
| | Hydrocortisone | 3 | 2018 | 298 | 0.350 |
Why?
| | Heart-Assist Devices | 3 | 2023 | 568 | 0.340 |
Why?
| | Quality of Life | 8 | 2022 | 3204 | 0.340 |
Why?
| | Hormone Antagonists | 1 | 2011 | 33 | 0.340 |
Why?
| | Baroreflex | 2 | 2022 | 57 | 0.340 |
Why?
| | Treatment Outcome | 18 | 2022 | 11772 | 0.340 |
Why?
| | Analysis of Variance | 11 | 2018 | 1300 | 0.330 |
Why?
| | Adipose Tissue, Brown | 2 | 2024 | 60 | 0.330 |
Why?
| | Cognition | 3 | 2013 | 1266 | 0.330 |
Why?
| | Physical Education and Training | 14 | 1996 | 70 | 0.330 |
Why?
| | Procollagen | 3 | 2020 | 24 | 0.330 |
Why?
| | Osteocalcin | 5 | 2022 | 38 | 0.330 |
Why?
| | Hip | 6 | 2012 | 57 | 0.320 |
Why?
| | Body Mass Index | 10 | 2019 | 2445 | 0.320 |
Why?
| | Women's Health | 4 | 2024 | 314 | 0.320 |
Why?
| | Ovariectomy | 5 | 2025 | 166 | 0.310 |
Why?
| | Sympathetic Nervous System | 1 | 2011 | 181 | 0.310 |
Why?
| | Glucose Intolerance | 5 | 2001 | 142 | 0.310 |
Why?
| | Disability Evaluation | 5 | 2013 | 310 | 0.310 |
Why?
| | Vasodilator Agents | 1 | 2012 | 330 | 0.310 |
Why?
| | Acetaminophen | 1 | 2012 | 267 | 0.300 |
Why?
| | Gravitation | 1 | 2009 | 22 | 0.300 |
Why?
| | Bone Density Conservation Agents | 2 | 2024 | 82 | 0.300 |
Why?
| | Sex Characteristics | 10 | 2024 | 782 | 0.300 |
Why?
| | HIV Infections | 8 | 2020 | 3194 | 0.300 |
Why?
| | Lipids | 6 | 2013 | 707 | 0.300 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 101 | 0.300 |
Why?
| | Menstrual Cycle | 2 | 2013 | 145 | 0.290 |
Why?
| | Cross-Sectional Studies | 15 | 2026 | 5905 | 0.290 |
Why?
| | Alkaline Phosphatase | 3 | 2021 | 144 | 0.290 |
Why?
| | Osteoarthritis | 2 | 2015 | 200 | 0.290 |
Why?
| | Adolescent | 16 | 2026 | 22530 | 0.280 |
Why?
| | Heart Failure | 4 | 2024 | 2326 | 0.280 |
Why?
| | Progesterone Congeners | 3 | 2003 | 8 | 0.280 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1217 | 0.280 |
Why?
| | Physical Exertion | 6 | 2001 | 205 | 0.280 |
Why?
| | Dyslipidemias | 1 | 2010 | 184 | 0.280 |
Why?
| | Range of Motion, Articular | 7 | 2017 | 429 | 0.270 |
Why?
| | Oxidative Stress | 6 | 2026 | 1356 | 0.270 |
Why?
| | Case-Control Studies | 8 | 2025 | 3623 | 0.270 |
Why?
| | Urine | 3 | 2004 | 64 | 0.270 |
Why?
| | Hematopoietic Stem Cells | 4 | 2025 | 435 | 0.270 |
Why?
| | Pain Measurement | 6 | 2018 | 561 | 0.260 |
Why?
| | Pain Threshold | 3 | 2018 | 72 | 0.260 |
Why?
| | Prospective Studies | 16 | 2019 | 8057 | 0.260 |
Why?
| | Sports | 5 | 2020 | 211 | 0.260 |
Why?
| | High-Intensity Interval Training | 2 | 2018 | 45 | 0.250 |
Why?
| | Circadian Rhythm | 4 | 2020 | 512 | 0.250 |
Why?
| | Peptide Fragments | 3 | 2020 | 693 | 0.250 |
Why?
| | Body Water | 2 | 2004 | 23 | 0.250 |
Why?
| | Area Under Curve | 6 | 2013 | 331 | 0.240 |
Why?
| | Triglycerides | 4 | 2011 | 520 | 0.240 |
Why?
| | Fractures, Bone | 4 | 2016 | 428 | 0.240 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2019 | 3922 | 0.240 |
Why?
| | Postural Balance | 6 | 2015 | 245 | 0.230 |
Why?
| | Sirtuins | 1 | 2026 | 50 | 0.230 |
Why?
| | Risk Factors | 12 | 2019 | 10885 | 0.220 |
Why?
| | Heart Ventricles | 2 | 2020 | 756 | 0.220 |
Why?
| | Radioisotope Dilution Technique | 2 | 2004 | 14 | 0.220 |
Why?
| | Water | 2 | 2019 | 445 | 0.220 |
Why?
| | Cardiac Output | 5 | 2023 | 179 | 0.220 |
Why?
| | Blood Coagulation | 1 | 2007 | 274 | 0.220 |
Why?
| | Cholesterol | 4 | 2011 | 408 | 0.220 |
Why?
| | Basal Metabolism | 1 | 2005 | 59 | 0.220 |
Why?
| | Alendronate | 1 | 2024 | 14 | 0.210 |
Why?
| | Bone Marrow Cells | 3 | 2021 | 321 | 0.210 |
Why?
| | Diet | 8 | 2019 | 1277 | 0.210 |
Why?
| | Body Constitution | 2 | 2001 | 51 | 0.210 |
Why?
| | Physical Conditioning, Animal | 5 | 2025 | 242 | 0.210 |
Why?
| | Serum | 1 | 2004 | 58 | 0.210 |
Why?
| | Cholesterol, HDL | 5 | 2011 | 201 | 0.210 |
Why?
| | Time Factors | 14 | 2019 | 7123 | 0.210 |
Why?
| | Regression Analysis | 6 | 2011 | 1001 | 0.200 |
Why?
| | Recovery of Function | 6 | 2017 | 716 | 0.200 |
Why?
| | Blood Pressure | 10 | 2022 | 1779 | 0.200 |
Why?
| | Placebos | 4 | 2011 | 193 | 0.190 |
Why?
| | Endothelin-1 | 1 | 2025 | 181 | 0.190 |
Why?
| | HIV-1 | 4 | 2013 | 908 | 0.190 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2024 | 161 | 0.190 |
Why?
| | Caloric Restriction | 1 | 2024 | 133 | 0.190 |
Why?
| | Adipose Tissue, White | 2 | 2024 | 43 | 0.190 |
Why?
| | Sports Medicine | 1 | 2004 | 118 | 0.190 |
Why?
| | Cardiorespiratory Fitness | 2 | 2024 | 74 | 0.190 |
Why?
| | Rats, Wistar | 1 | 2024 | 450 | 0.190 |
Why?
| | Diet, Reducing | 2 | 2001 | 91 | 0.180 |
Why?
| | Arginine | 4 | 2017 | 264 | 0.180 |
Why?
| | Cold Temperature | 2 | 2024 | 206 | 0.180 |
Why?
| | Thermogenesis | 2 | 2024 | 45 | 0.180 |
Why?
| | Intermittent Claudication | 2 | 2015 | 122 | 0.180 |
Why?
| | Torque | 2 | 2012 | 82 | 0.170 |
Why?
| | Circadian Clocks | 2 | 2019 | 59 | 0.170 |
Why?
| | Insulin-Like Growth Factor I | 5 | 2013 | 317 | 0.170 |
Why?
| | Knee Joint | 6 | 2017 | 428 | 0.170 |
Why?
| | Oxygen Isotopes | 2 | 2019 | 24 | 0.170 |
Why?
| | Vitamin D | 3 | 2020 | 403 | 0.170 |
Why?
| | Ventricular Function, Right | 2 | 2020 | 297 | 0.170 |
Why?
| | Weight Reduction Programs | 2 | 2014 | 140 | 0.170 |
Why?
| | Ultrasonography | 7 | 2018 | 785 | 0.170 |
Why?
| | Proteins | 5 | 1998 | 1023 | 0.170 |
Why?
| | Pressoreceptors | 1 | 2021 | 19 | 0.170 |
Why?
| | Intestinal Absorption | 1 | 2001 | 103 | 0.160 |
Why?
| | Polysaccharides | 2 | 2021 | 86 | 0.160 |
Why?
| | Dexamethasone | 2 | 2018 | 365 | 0.160 |
Why?
| | Glycosylation | 2 | 2021 | 173 | 0.160 |
Why?
| | Postprandial Period | 1 | 2001 | 114 | 0.160 |
Why?
| | Muscle Proteins | 3 | 2019 | 242 | 0.160 |
Why?
| | Pulmonary Gas Exchange | 5 | 2017 | 116 | 0.160 |
Why?
| | Hip Joint | 3 | 2019 | 173 | 0.160 |
Why?
| | Cross-Over Studies | 3 | 2014 | 608 | 0.160 |
Why?
| | Lactates | 8 | 2012 | 82 | 0.160 |
Why?
| | Animals | 23 | 2025 | 38030 | 0.160 |
Why?
| | Interleukin-6 | 2 | 2022 | 776 | 0.160 |
Why?
| | Luteal Phase | 2 | 2014 | 51 | 0.160 |
Why?
| | Carbohydrate Metabolism | 3 | 1998 | 59 | 0.150 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2023 | 394 | 0.150 |
Why?
| | Age Factors | 7 | 2025 | 3342 | 0.150 |
Why?
| | Research Design | 4 | 2024 | 1137 | 0.150 |
Why?
| | Oxidation-Reduction | 5 | 2020 | 1067 | 0.150 |
Why?
| | Endothelial Cells | 1 | 2026 | 874 | 0.150 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 29 | 0.150 |
Why?
| | Reference Values | 6 | 2013 | 798 | 0.150 |
Why?
| | Pilot Projects | 6 | 2020 | 1891 | 0.150 |
Why?
| | Coronary Disease | 2 | 2001 | 381 | 0.150 |
Why?
| | Myocardial Contraction | 1 | 2020 | 293 | 0.150 |
Why?
| | Mitochondria | 1 | 2026 | 992 | 0.150 |
Why?
| | Surveys and Questionnaires | 8 | 2019 | 6066 | 0.150 |
Why?
| | Adjuvants, Immunologic | 1 | 2000 | 243 | 0.140 |
Why?
| | Patient Compliance | 4 | 2015 | 587 | 0.140 |
Why?
| | Sleep Disorders, Circadian Rhythm | 1 | 2019 | 52 | 0.140 |
Why?
| | Cholesterol, LDL | 4 | 2011 | 360 | 0.140 |
Why?
| | Health Behavior | 1 | 2004 | 789 | 0.140 |
Why?
| | Calcium Channels, L-Type | 1 | 2019 | 117 | 0.140 |
Why?
| | Compliance | 2 | 2018 | 50 | 0.140 |
Why?
| | Acidosis | 1 | 2019 | 105 | 0.140 |
Why?
| | Homocysteine | 1 | 2019 | 152 | 0.140 |
Why?
| | Extracellular Fluid | 1 | 2018 | 38 | 0.140 |
Why?
| | Geographic Atrophy | 1 | 2019 | 97 | 0.140 |
Why?
| | Cortisone | 1 | 2018 | 16 | 0.140 |
Why?
| | Swimming | 2 | 1989 | 54 | 0.140 |
Why?
| | Proof of Concept Study | 1 | 2018 | 89 | 0.140 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2019 | 212 | 0.140 |
Why?
| | Ions | 1 | 2018 | 66 | 0.140 |
Why?
| | Cancellous Bone | 1 | 2017 | 22 | 0.130 |
Why?
| | Osteoarthritis, Hip | 1 | 2018 | 45 | 0.130 |
Why?
| | Obesity, Abdominal | 2 | 2017 | 47 | 0.130 |
Why?
| | Cysteine | 1 | 2019 | 211 | 0.130 |
Why?
| | omega-N-Methylarginine | 1 | 1997 | 29 | 0.130 |
Why?
| | Cardiovascular Physiological Phenomena | 3 | 2015 | 48 | 0.130 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2018 | 147 | 0.130 |
Why?
| | Macular Degeneration | 1 | 2019 | 191 | 0.130 |
Why?
| | Rest | 2 | 1997 | 124 | 0.130 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2020 | 248 | 0.130 |
Why?
| | Growth Hormone | 1 | 1997 | 91 | 0.130 |
Why?
| | Physical Therapy Modalities | 2 | 2012 | 336 | 0.130 |
Why?
| | Isotope Labeling | 1 | 2017 | 82 | 0.130 |
Why?
| | Integrin beta1 | 1 | 2017 | 33 | 0.130 |
Why?
| | Galactose | 1 | 2017 | 34 | 0.130 |
Why?
| | Forearm | 1 | 1997 | 141 | 0.120 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2018 | 128 | 0.120 |
Why?
| | Hypokinesia | 1 | 2016 | 11 | 0.120 |
Why?
| | Healthy Volunteers | 2 | 2017 | 219 | 0.120 |
Why?
| | Luteinizing Hormone | 2 | 2015 | 207 | 0.120 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2019 | 2588 | 0.120 |
Why?
| | Pelvic Bones | 1 | 2018 | 134 | 0.120 |
Why?
| | Gait Disorders, Neurologic | 1 | 2017 | 44 | 0.120 |
Why?
| | Osteoporotic Fractures | 1 | 2017 | 62 | 0.120 |
Why?
| | Lipid Metabolism | 3 | 1998 | 529 | 0.120 |
Why?
| | Hyperinsulinism | 3 | 2003 | 114 | 0.120 |
Why?
| | Vascular Diseases | 1 | 2019 | 252 | 0.120 |
Why?
| | Peripheral Arterial Disease | 2 | 2015 | 507 | 0.120 |
Why?
| | Electromyography | 2 | 2016 | 419 | 0.120 |
Why?
| | Food, Fortified | 1 | 2016 | 44 | 0.120 |
Why?
| | Mice | 8 | 2025 | 18329 | 0.120 |
Why?
| | Administration, Cutaneous | 3 | 2015 | 127 | 0.120 |
Why?
| | Pain | 1 | 2001 | 789 | 0.120 |
Why?
| | Stroke Volume | 6 | 2023 | 654 | 0.120 |
Why?
| | Adipocytes, White | 1 | 2015 | 19 | 0.120 |
Why?
| | Energy Intake | 5 | 2013 | 512 | 0.110 |
Why?
| | Nitric Oxide | 2 | 2017 | 892 | 0.110 |
Why?
| | Gonadotropins | 1 | 2015 | 44 | 0.110 |
Why?
| | Muscle Strength Dynamometer | 2 | 2012 | 24 | 0.110 |
Why?
| | Aging, Premature | 2 | 2013 | 16 | 0.110 |
Why?
| | Predictive Value of Tests | 4 | 2015 | 2121 | 0.110 |
Why?
| | Injections, Intravenous | 2 | 2006 | 197 | 0.110 |
Why?
| | Muscles | 7 | 2013 | 330 | 0.110 |
Why?
| | Wrist Joint | 1 | 1995 | 71 | 0.110 |
Why?
| | Stem Cells | 2 | 2017 | 628 | 0.110 |
Why?
| | Precision Medicine | 1 | 2019 | 459 | 0.110 |
Why?
| | Metabolomics | 1 | 2020 | 732 | 0.100 |
Why?
| | Minimally Invasive Surgical Procedures | 2 | 2012 | 189 | 0.100 |
Why?
| | Mass Spectrometry | 1 | 2017 | 730 | 0.100 |
Why?
| | Linear Models | 2 | 2008 | 845 | 0.100 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 5983 | 0.100 |
Why?
| | Clinical Trials as Topic | 4 | 2016 | 1061 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2015 | 2028 | 0.100 |
Why?
| | Accidental Falls | 2 | 2017 | 226 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 3 | 2014 | 2769 | 0.100 |
Why?
| | Etanercept | 1 | 2013 | 60 | 0.100 |
Why?
| | Catecholamines | 1 | 1993 | 88 | 0.100 |
Why?
| | Neck Pain | 1 | 2013 | 30 | 0.100 |
Why?
| | Spine | 1 | 1995 | 182 | 0.100 |
Why?
| | Health Status Indicators | 2 | 2011 | 167 | 0.100 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 130 | 0.100 |
Why?
| | Anti-HIV Agents | 4 | 2014 | 912 | 0.100 |
Why?
| | Radiography | 2 | 2012 | 852 | 0.100 |
Why?
| | Community Health Services | 1 | 2015 | 231 | 0.100 |
Why?
| | Longitudinal Studies | 4 | 2018 | 2953 | 0.090 |
Why?
| | C-Reactive Protein | 2 | 2022 | 422 | 0.090 |
Why?
| | Anti-Retroviral Agents | 1 | 2015 | 251 | 0.090 |
Why?
| | Follow-Up Studies | 5 | 2018 | 5423 | 0.090 |
Why?
| | Life Style | 3 | 2008 | 485 | 0.090 |
Why?
| | Microfluidics | 1 | 2013 | 61 | 0.090 |
Why?
| | Superoxide Dismutase | 1 | 2015 | 308 | 0.090 |
Why?
| | Sex Hormone-Binding Globulin | 2 | 2013 | 52 | 0.090 |
Why?
| | Acupressure | 1 | 2012 | 9 | 0.090 |
Why?
| | Mathematical Concepts | 1 | 2013 | 35 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2005 | 1997 | 0.090 |
Why?
| | Hunger | 1 | 2013 | 56 | 0.090 |
Why?
| | Femoral Neck Fractures | 1 | 2012 | 21 | 0.090 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 1044 | 0.090 |
Why?
| | Steroids | 1 | 2013 | 160 | 0.090 |
Why?
| | Myofascial Pain Syndromes | 1 | 2012 | 12 | 0.090 |
Why?
| | Carbon Isotopes | 2 | 2006 | 143 | 0.090 |
Why?
| | Posture | 1 | 1993 | 197 | 0.090 |
Why?
| | Receptors, CCR5 | 1 | 2012 | 60 | 0.090 |
Why?
| | Cervix Uteri | 1 | 2012 | 50 | 0.090 |
Why?
| | Spinal Fractures | 1 | 2012 | 76 | 0.090 |
Why?
| | Hemodynamics | 4 | 2023 | 1118 | 0.090 |
Why?
| | Neuropsychological Tests | 2 | 2015 | 1134 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 249 | 0.090 |
Why?
| | Sarcopenia | 1 | 2013 | 91 | 0.090 |
Why?
| | HIV Seropositivity | 1 | 2012 | 119 | 0.090 |
Why?
| | Hysterectomy | 1 | 2012 | 138 | 0.090 |
Why?
| | Gait | 4 | 2015 | 312 | 0.090 |
Why?
| | Incidence | 3 | 2019 | 2923 | 0.090 |
Why?
| | Meals | 1 | 2013 | 130 | 0.090 |
Why?
| | Oxytocics | 1 | 2011 | 15 | 0.080 |
Why?
| | Headache | 1 | 2012 | 151 | 0.080 |
Why?
| | Chromatography, Liquid | 1 | 2013 | 450 | 0.080 |
Why?
| | Fatty Acids, Nonesterified | 5 | 2001 | 154 | 0.080 |
Why?
| | Muscle Fatigue | 1 | 2012 | 98 | 0.080 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2012 | 237 | 0.080 |
Why?
| | Kinetics | 5 | 2003 | 1567 | 0.080 |
Why?
| | Combined Modality Therapy | 3 | 2013 | 1266 | 0.080 |
Why?
| | Cartilage, Articular | 1 | 2015 | 349 | 0.080 |
Why?
| | Longevity | 2 | 2024 | 178 | 0.080 |
Why?
| | Perception | 2 | 2013 | 378 | 0.080 |
Why?
| | Dinoprostone | 1 | 2011 | 180 | 0.080 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 527 | 0.080 |
Why?
| | Athletes | 1 | 2014 | 424 | 0.080 |
Why?
| | Single-Blind Method | 3 | 2016 | 318 | 0.080 |
Why?
| | Parity | 1 | 2010 | 111 | 0.080 |
Why?
| | Tandem Mass Spectrometry | 1 | 2013 | 572 | 0.080 |
Why?
| | Contraceptive Agents | 1 | 2010 | 66 | 0.080 |
Why?
| | Bayes Theorem | 2 | 2022 | 420 | 0.070 |
Why?
| | Cohort Studies | 2 | 2012 | 6013 | 0.070 |
Why?
| | Hypoglycemic Agents | 1 | 1999 | 1399 | 0.070 |
Why?
| | Androgens | 2 | 2017 | 181 | 0.070 |
Why?
| | Carbon Dioxide | 2 | 2010 | 227 | 0.070 |
Why?
| | Efficiency | 1 | 1989 | 103 | 0.070 |
Why?
| | Antiparkinson Agents | 2 | 2022 | 41 | 0.070 |
Why?
| | Respiration | 4 | 2015 | 206 | 0.070 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 857 | 0.070 |
Why?
| | Bone Diseases, Metabolic | 2 | 2019 | 58 | 0.070 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2013 | 1140 | 0.070 |
Why?
| | Chronic Pain | 1 | 2013 | 291 | 0.070 |
Why?
| | Muscle Contraction | 1 | 2011 | 429 | 0.070 |
Why?
| | Rats | 8 | 2024 | 5584 | 0.070 |
Why?
| | Depression | 1 | 2018 | 1546 | 0.070 |
Why?
| | Statistics as Topic | 1 | 2009 | 283 | 0.070 |
Why?
| | Calcium Citrate | 1 | 2008 | 1 | 0.070 |
Why?
| | Advance Care Planning | 1 | 2012 | 244 | 0.070 |
Why?
| | Mechanotransduction, Cellular | 1 | 2009 | 121 | 0.070 |
Why?
| | Spectrum Analysis | 2 | 2019 | 85 | 0.070 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 782 | 0.070 |
Why?
| | Executive Function | 1 | 2013 | 470 | 0.070 |
Why?
| | Dietary Fats | 4 | 2013 | 308 | 0.070 |
Why?
| | Cytokines | 1 | 2015 | 2067 | 0.070 |
Why?
| | Ventricular Function, Left | 3 | 2023 | 542 | 0.060 |
Why?
| | Low Back Pain | 1 | 2008 | 107 | 0.060 |
Why?
| | Norepinephrine | 2 | 2021 | 201 | 0.060 |
Why?
| | Leg | 3 | 2002 | 242 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2018 | 1547 | 0.060 |
Why?
| | Carrier Proteins | 2 | 2005 | 728 | 0.060 |
Why?
| | Electric Stimulation | 1 | 2007 | 276 | 0.060 |
Why?
| | Cell Differentiation | 3 | 2021 | 2046 | 0.060 |
Why?
| | Risk Reduction Behavior | 1 | 2008 | 217 | 0.060 |
Why?
| | Transcription, Genetic | 1 | 2012 | 1454 | 0.060 |
Why?
| | Glycoproteins | 2 | 2021 | 354 | 0.060 |
Why?
| | Densitometry | 2 | 1998 | 36 | 0.060 |
Why?
| | Radioimmunoassay | 1 | 2005 | 165 | 0.060 |
Why?
| | Buttocks | 1 | 2005 | 14 | 0.060 |
Why?
| | Immunoenzyme Techniques | 1 | 2005 | 200 | 0.060 |
Why?
| | Follicular Phase | 1 | 2005 | 41 | 0.060 |
Why?
| | Blood Coagulation Disorders | 1 | 2007 | 198 | 0.050 |
Why?
| | Cell Lineage | 2 | 2017 | 377 | 0.050 |
Why?
| | Nutritional Status | 2 | 2019 | 353 | 0.050 |
Why?
| | Calorimetry, Indirect | 2 | 2017 | 72 | 0.050 |
Why?
| | Colorado | 4 | 2019 | 4554 | 0.050 |
Why?
| | Logistic Models | 2 | 2019 | 2134 | 0.050 |
Why?
| | Administration, Oral | 2 | 2018 | 866 | 0.050 |
Why?
| | Pulse Wave Analysis | 1 | 2024 | 267 | 0.050 |
Why?
| | Plethysmography | 2 | 2022 | 104 | 0.050 |
Why?
| | Endometrium | 1 | 2003 | 64 | 0.050 |
Why?
| | Models, Animal | 1 | 2004 | 393 | 0.050 |
Why?
| | Statistics, Nonparametric | 2 | 2015 | 428 | 0.050 |
Why?
| | ADP-ribosyl Cyclase 1 | 2 | 2013 | 43 | 0.050 |
Why?
| | Liver | 3 | 2024 | 1896 | 0.050 |
Why?
| | CD4 Lymphocyte Count | 2 | 2013 | 280 | 0.050 |
Why?
| | Skinfold Thickness | 2 | 1992 | 43 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 116 | 0.050 |
Why?
| | Disease Progression | 1 | 2010 | 2864 | 0.050 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2022 | 59 | 0.050 |
Why?
| | Positron-Emission Tomography | 1 | 2024 | 343 | 0.040 |
Why?
| | Diphtheria Toxin | 1 | 2022 | 65 | 0.040 |
Why?
| | Retrospective Studies | 5 | 2019 | 17291 | 0.040 |
Why?
| | Preoperative Period | 2 | 2014 | 149 | 0.040 |
Why?
| | Food Deprivation | 2 | 2000 | 28 | 0.040 |
Why?
| | Osteocytes | 1 | 2001 | 24 | 0.040 |
Why?
| | Knee | 2 | 1997 | 72 | 0.040 |
Why?
| | Eating | 2 | 2001 | 387 | 0.040 |
Why?
| | Lipoproteins | 2 | 2000 | 166 | 0.040 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2022 | 154 | 0.040 |
Why?
| | Movement | 2 | 2014 | 293 | 0.040 |
Why?
| | Postoperative Period | 2 | 2014 | 351 | 0.040 |
Why?
| | Survival Analysis | 2 | 2015 | 1374 | 0.040 |
Why?
| | Hyperlipidemias | 1 | 2002 | 120 | 0.040 |
Why?
| | Ultrasonography, Doppler | 1 | 2022 | 126 | 0.040 |
Why?
| | Valsalva Maneuver | 1 | 2021 | 9 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2005 | 531 | 0.040 |
Why?
| | Tibia | 2 | 2019 | 176 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 412 | 0.040 |
Why?
| | Signal Transduction | 2 | 2021 | 5216 | 0.040 |
Why?
| | Stress, Mechanical | 2 | 2001 | 494 | 0.040 |
Why?
| | Musculoskeletal Physiological Phenomena | 1 | 2000 | 8 | 0.040 |
Why?
| | Respiratory Mechanics | 1 | 2000 | 74 | 0.040 |
Why?
| | Adiponectin | 1 | 2022 | 241 | 0.040 |
Why?
| | Blood Flow Velocity | 1 | 2022 | 421 | 0.040 |
Why?
| | Kidney | 2 | 1998 | 1497 | 0.040 |
Why?
| | Mice, Transgenic | 2 | 2015 | 2188 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2020 | 171 | 0.040 |
Why?
| | Electric Conductivity | 1 | 2019 | 85 | 0.040 |
Why?
| | Child Development | 1 | 1985 | 483 | 0.040 |
Why?
| | Blood Circulation | 1 | 1999 | 44 | 0.040 |
Why?
| | Orchiectomy | 1 | 2019 | 72 | 0.040 |
Why?
| | Fasting | 1 | 2001 | 279 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 99 | 0.040 |
Why?
| | Hand Strength | 1 | 2000 | 144 | 0.040 |
Why?
| | Electrocardiography | 2 | 2020 | 665 | 0.040 |
Why?
| | Muscle Development | 1 | 2000 | 112 | 0.040 |
Why?
| | Anthropometry | 2 | 2017 | 206 | 0.040 |
Why?
| | Radius | 1 | 2019 | 51 | 0.040 |
Why?
| | Physician's Role | 1 | 2001 | 224 | 0.040 |
Why?
| | Collagen | 1 | 2001 | 457 | 0.040 |
Why?
| | Attitude | 1 | 2001 | 259 | 0.040 |
Why?
| | Physical Conditioning, Human | 1 | 2019 | 38 | 0.040 |
Why?
| | Congresses as Topic | 1 | 2020 | 223 | 0.040 |
Why?
| | Antioxidants | 1 | 2022 | 550 | 0.030 |
Why?
| | Actigraphy | 1 | 2019 | 148 | 0.030 |
Why?
| | Injections, Intra-Articular | 1 | 2018 | 58 | 0.030 |
Why?
| | North Carolina | 1 | 2018 | 129 | 0.030 |
Why?
| | Socioeconomic Factors | 2 | 2013 | 1323 | 0.030 |
Why?
| | Isometric Contraction | 2 | 2010 | 190 | 0.030 |
Why?
| | Administration, Topical | 1 | 2018 | 153 | 0.030 |
Why?
| | Cardiovascular System | 1 | 2019 | 138 | 0.030 |
Why?
| | Conservative Treatment | 1 | 2018 | 45 | 0.030 |
Why?
| | Ventricular Remodeling | 1 | 2000 | 278 | 0.030 |
Why?
| | Estrogen Receptor alpha | 1 | 2019 | 151 | 0.030 |
Why?
| | Feasibility Studies | 2 | 2015 | 1111 | 0.030 |
Why?
| | Transcriptome | 1 | 2024 | 1038 | 0.030 |
Why?
| | Mental Health | 2 | 2015 | 793 | 0.030 |
Why?
| | Hamstring Muscles | 1 | 2017 | 22 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 425 | 0.030 |
Why?
| | Goserelin | 1 | 2017 | 8 | 0.030 |
Why?
| | Nephrectomy | 1 | 1998 | 163 | 0.030 |
Why?
| | Fertility Agents, Female | 1 | 2017 | 23 | 0.030 |
Why?
| | Pregnancy | 1 | 2010 | 7202 | 0.030 |
Why?
| | Blood | 2 | 1995 | 107 | 0.030 |
Why?
| | Psychometrics | 1 | 2001 | 731 | 0.030 |
Why?
| | Blood Chemical Analysis | 1 | 1997 | 109 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 558 | 0.030 |
Why?
| | Adipogenesis | 1 | 2017 | 56 | 0.030 |
Why?
| | Cell Size | 1 | 1996 | 92 | 0.030 |
Why?
| | Fibrin | 1 | 2017 | 84 | 0.030 |
Why?
| | Aromatase Inhibitors | 1 | 2017 | 78 | 0.030 |
Why?
| | Joints | 1 | 1997 | 106 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 1989 | 3904 | 0.030 |
Why?
| | Heart | 1 | 2020 | 626 | 0.030 |
Why?
| | Accelerometry | 1 | 2017 | 118 | 0.030 |
Why?
| | Glycogen | 1 | 1996 | 55 | 0.030 |
Why?
| | Cell Fusion | 1 | 2015 | 48 | 0.030 |
Why?
| | Child | 3 | 2024 | 22707 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 1998 | 266 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2017 | 147 | 0.030 |
Why?
| | Monosaccharide Transport Proteins | 1 | 1996 | 56 | 0.030 |
Why?
| | Ambulatory Care Facilities | 1 | 2018 | 269 | 0.030 |
Why?
| | Affect | 1 | 2018 | 320 | 0.030 |
Why?
| | Mental Status Schedule | 1 | 2015 | 35 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2823 | 0.030 |
Why?
| | Human Activities | 1 | 2015 | 20 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 1995 | 164 | 0.030 |
Why?
| | Calibration | 1 | 1995 | 152 | 0.030 |
Why?
| | Fatty Acids | 1 | 1998 | 457 | 0.030 |
Why?
| | Neurophysiology | 1 | 2015 | 13 | 0.030 |
Why?
| | Intention to Treat Analysis | 1 | 2015 | 79 | 0.030 |
Why?
| | Databases, Bibliographic | 1 | 2015 | 30 | 0.030 |
Why?
| | Capillaries | 1 | 1996 | 125 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 1998 | 337 | 0.030 |
Why?
| | Muscular Atrophy | 1 | 1995 | 87 | 0.030 |
Why?
| | Arthrometry, Articular | 1 | 2014 | 9 | 0.030 |
Why?
| | Models, Statistical | 1 | 2019 | 671 | 0.030 |
Why?
| | Self Report | 1 | 2019 | 870 | 0.030 |
Why?
| | Alzheimer Disease | 1 | 2001 | 630 | 0.030 |
Why?
| | Progesterone | 1 | 2015 | 215 | 0.030 |
Why?
| | Cholesterol Esters | 1 | 1993 | 7 | 0.030 |
Why?
| | Models, Biological | 2 | 1999 | 1764 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2007 | 3413 | 0.030 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 32 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2018 | 609 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2013 | 46 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2015 | 279 | 0.020 |
Why?
| | Lost to Follow-Up | 1 | 2013 | 20 | 0.020 |
Why?
| | Citrates | 1 | 1993 | 41 | 0.020 |
Why?
| | Calorimetry | 1 | 2013 | 69 | 0.020 |
Why?
| | Anaerobic Threshold | 1 | 1992 | 28 | 0.020 |
Why?
| | Epinephrine | 1 | 1993 | 158 | 0.020 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 174 | 0.020 |
Why?
| | Comorbidity | 1 | 1998 | 1661 | 0.020 |
Why?
| | Ascorbic Acid | 1 | 2014 | 184 | 0.020 |
Why?
| | Patient Dropouts | 1 | 2013 | 65 | 0.020 |
Why?
| | United States | 1 | 2010 | 16098 | 0.020 |
Why?
| | Appetite | 1 | 2013 | 80 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2865 | 0.020 |
Why?
| | Dietary Carbohydrates | 1 | 2013 | 147 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2015 | 614 | 0.020 |
Why?
| | Blood Loss, Surgical | 1 | 2012 | 113 | 0.020 |
Why?
| | Somatomedins | 1 | 1991 | 28 | 0.020 |
Why?
| | Upper Extremity | 1 | 2013 | 113 | 0.020 |
Why?
| | Dietary Proteins | 1 | 2013 | 135 | 0.020 |
Why?
| | Counseling | 1 | 2015 | 400 | 0.020 |
Why?
| | Apolipoproteins B | 1 | 1991 | 47 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 330 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2013 | 279 | 0.020 |
Why?
| | Hypertension | 1 | 2000 | 1273 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2012 | 220 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 2013 | 239 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 1246 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2011 | 62 | 0.020 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2017 | 699 | 0.020 |
Why?
| | Viral Load | 1 | 2013 | 526 | 0.020 |
Why?
| | Registries | 1 | 2019 | 2406 | 0.020 |
Why?
| | Program Evaluation | 1 | 2015 | 943 | 0.020 |
Why?
| | Glycogen Storage Disease Type V | 1 | 1990 | 1 | 0.020 |
Why?
| | Computational Biology | 1 | 2015 | 669 | 0.020 |
Why?
| | Physical Phenomena | 1 | 2010 | 13 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2013 | 499 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2012 | 344 | 0.020 |
Why?
| | Blood Vessels | 1 | 1991 | 167 | 0.020 |
Why?
| | Hyperglycemia | 2 | 1991 | 379 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2597 | 0.020 |
Why?
| | Odds Ratio | 1 | 2012 | 1082 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4148 | 0.020 |
Why?
| | Spirometry | 1 | 2010 | 233 | 0.020 |
Why?
| | Macrophages | 1 | 2017 | 1507 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 1132 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1041 | 0.020 |
Why?
| | Body Temperature | 1 | 2010 | 227 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 3 | 2000 | 2524 | 0.020 |
Why?
| | Overweight | 1 | 2014 | 614 | 0.020 |
Why?
| | Pain Management | 1 | 2012 | 410 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3747 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2010 | 544 | 0.020 |
Why?
| | Iodine Radioisotopes | 2 | 1998 | 136 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2008 | 251 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2013 | 4560 | 0.020 |
Why?
| | Respiratory Muscles | 1 | 1987 | 37 | 0.020 |
Why?
| | Body Fluids | 1 | 1987 | 71 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 919 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2007 | 198 | 0.010 |
Why?
| | Prognosis | 1 | 2014 | 4316 | 0.010 |
Why?
| | DNA | 1 | 2012 | 1435 | 0.010 |
Why?
| | Aerobiosis | 1 | 1985 | 18 | 0.010 |
Why?
| | Neoplasms | 1 | 2001 | 2906 | 0.010 |
Why?
| | Shoes | 1 | 1985 | 19 | 0.010 |
Why?
| | Orthotic Devices | 1 | 1985 | 27 | 0.010 |
Why?
| | Endometrial Hyperplasia | 1 | 2003 | 6 | 0.010 |
Why?
| | Body Height | 1 | 1985 | 202 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 2008 | 777 | 0.010 |
Why?
| | Uterine Hemorrhage | 1 | 2003 | 41 | 0.010 |
Why?
| | Inflammation | 1 | 2013 | 2878 | 0.010 |
Why?
| | Psychomotor Performance | 1 | 2004 | 324 | 0.010 |
Why?
| | Vascular Resistance | 2 | 1993 | 370 | 0.010 |
Why?
| | Matched-Pair Analysis | 1 | 2000 | 37 | 0.010 |
Why?
| | Infusions, Intravenous | 2 | 1991 | 428 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2012 | 2970 | 0.010 |
Why?
| | Biopsy | 1 | 2003 | 1082 | 0.010 |
Why?
| | Isoflavones | 1 | 1999 | 25 | 0.010 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2000 | 124 | 0.010 |
Why?
| | Hindlimb | 1 | 2000 | 132 | 0.010 |
Why?
| | Rats, Long-Evans | 1 | 1999 | 128 | 0.010 |
Why?
| | Vibration | 1 | 1999 | 70 | 0.010 |
Why?
| | Organ Size | 1 | 2000 | 461 | 0.010 |
Why?
| | Elasticity | 1 | 1999 | 189 | 0.010 |
Why?
| | Uterus | 1 | 2000 | 227 | 0.010 |
Why?
| | Acoustic Stimulation | 1 | 1999 | 333 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1997 | 115 | 0.010 |
Why?
| | Analgesics | 1 | 1999 | 231 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1997 | 335 | 0.010 |
Why?
| | Creatinine | 1 | 1998 | 515 | 0.010 |
Why?
| | Glucose Transporter Type 4 | 1 | 1996 | 39 | 0.010 |
Why?
| | Cholesterol Ester Transfer Proteins | 1 | 1993 | 22 | 0.010 |
Why?
| | Citric Acid | 1 | 1993 | 33 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1993 | 168 | 0.010 |
Why?
| | Citrate (si)-Synthase | 1 | 1992 | 57 | 0.010 |
Why?
| | Breath Tests | 1 | 1992 | 77 | 0.010 |
Why?
| | Cell Membrane | 1 | 1996 | 707 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 1991 | 69 | 0.010 |
Why?
| | Hormones | 1 | 1992 | 135 | 0.010 |
Why?
| | Mitochondria, Muscle | 1 | 1992 | 120 | 0.010 |
Why?
| | Glucosephosphates | 1 | 1990 | 3 | 0.010 |
Why?
| | Glucose-6-Phosphate | 1 | 1990 | 6 | 0.010 |
Why?
| | Hypercholesterolemia | 1 | 1991 | 95 | 0.010 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 1990 | 13 | 0.010 |
Why?
| | Lipoproteins, HDL2 | 1 | 1990 | 2 | 0.000 |
Why?
| | C-Peptide | 1 | 1991 | 190 | 0.000 |
Why?
| | Heart Diseases | 1 | 1993 | 341 | 0.000 |
Why?
| | Lipoproteins, HDL | 1 | 1990 | 100 | 0.000 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1990 | 531 | 0.000 |
Why?
| | Fatigue | 1 | 1991 | 364 | 0.000 |
Why?
| | Erythrocyte Volume | 1 | 1987 | 6 | 0.000 |
Why?
| | Maximal Voluntary Ventilation | 1 | 1987 | 9 | 0.000 |
Why?
| | Plasma Volume | 1 | 1987 | 20 | 0.000 |
Why?
| | Oxygen | 1 | 1985 | 978 | 0.000 |
Why?
|
|
Kohrt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|